Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“No better news to start the week: in TROPION-Breast02, first-line datopotamab deruxtecan improved PFS and OS over chemo for IO-ineligible patients with metastatic TNBC.
ADCs keep delivering, are rapidly climbing to earlier lines of treatment across breast cancer subtypes.
Hope to see the full results at ESMO25.”
More posts featuring Paolo Tarantino.